Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
ALAMEDA, CA—Johanna Roberts, Executive Vice President, General Counsel & Secretary of Penumbra Inc . (NYSE:PEN), recently executed a series of stock transactions as detailed in a recent SEC filing. On May 12, 2025, Roberts sold a total of 600 shares of Penumbra common stock, generating proceeds of approximately $268,697. The shares were sold at prices ranging from $292.86 to $300.94 per share.
In addition to the stock sales, Roberts also acquired 55 shares through the exercise of stock options at a price of $22.04 per share, amounting to a total transaction value of $1,212. Following these transactions, Roberts holds a total of 65,314 shares of Penumbra stock, a company that has demonstrated strong financial health with a ~13% revenue growth in the last twelve months.
These sales were conducted as part of Roberts’ Rule 10b5-1 trading plan, which allows company insiders to sell a predetermined number of shares at a set time, minimizing concerns of insider trading. For deeper insights into Penumbra’s valuation and comprehensive analysis, including 13 additional ProTips and detailed financial metrics, investors can access the full Pro Research Report on InvestingPro.
In other recent news, Penumbra reported a strong financial performance, with sales reaching $324.1 million, marking a 16.3% increase from the previous year, and earnings per share (EPS) rising to $0.83, a 102.8% jump. These figures exceeded Wall Street estimates by 2.7% and 24.4%, respectively, largely driven by the U.S. Thrombectomy business, which saw a 25% increase in sales. UBS analyst Priya Sachdeva raised the price target for Penumbra shares to $330, citing confidence in the company’s growth trajectory and maintaining a Buy rating. Stifel analyst Matthew Blackman also increased the price target to $318, following Penumbra’s first-quarter results for 2025, which surpassed expectations. BTIG analyst Ryan Zimmerman raised the firm’s price target to $320, highlighting Penumbra’s strong position in the market and its favorable outlook in the MedTech industry.
Additionally, Piper Sandler analyst Matt O’Brien noted that Penumbra’s Thunderbolt product might receive regulatory approval sooner than anticipated, potentially boosting the company’s revenue as the market has not yet accounted for Thunderbolt sales this fiscal year. Penumbra’s management reaffirmed its guidance for the year, projecting a 12-14% revenue increase, translating to a target range of $1.34 billion to $1.36 billion. The company’s strategic focus on the U.S. market, particularly in thrombectomy, positions it well for continued success. Analysts remain optimistic about Penumbra’s potential to outperform market expectations and deliver value to shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.